Free Newsletter
Israeli group creating fund for drug research
The Israeli Life Sciences Industry group is helping set up a $300 million to $500 million initiative to spur the development of biotechnology and help finance drug research in the country. Chief Scientist Dr. Eli Opper says that the country is already in negotiations with multinational biotech companies to create development centers in Israel while the government is adding to the biotech/nanotech activities of Israel's universities. Care Capital partner Dr. Argeris N. Karabelas told the group that development collaborations with major companies were the best tool to engineering success in the field.
- read the report from Globes
Related Article:
Biotech Valley planned for Israel. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
